Skip to main
ABVX

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 58%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Abivax is a biotechnology company with promising prospects in the development of a potential treatment for ulcerative colitis, obefazimod. While the company has potential for success in trials and collaborations in drug development, they also face challenges such as competition and potential safety concerns. With a primary strategic plan focused on M&A, the company's success may depend on their ability to overcome these risks and effectively market their drug. Analysts and industry experts are optimistic about the potential for growth in the IBD treatment market, providing a positive outlook for Abivax's stock.

Bears say

Abivax is a company with potential for upside if acquired, but also faces limitations with their drug obefazimod and potential competition in the growing market for IBD treatments. Additionally, their stock may suffer if acquisition fails and they may need additional financing.

Abivax SA (ABVX) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 58% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 12 analysts, Abivax SA (ABVX) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $132.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $132.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.